Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab

A L Chew; A Bennett; C H Smith; J Barker; B Kirkham

doi:10.1111/j.1365-2133.2004.06105.x

Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab

A L Chew, A Bennett, C H Smith, J Barker, B Kirkham

Dermatology

Research output: Contribution to journal › Article › peer-review

Abstract

Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-alpha, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis. We report two patients with long-standing recalcitrant psoriasis and psoriatic arthritis who, after multiple treatment failures with conventional and experimental antipsoriatic medications, both responded to treatment with adalimumab. Significant clinical improvement was noted in both skin and joint disease in the two patients after several weeks of treatment with adalimumab. We are unaware of previous published reports of adalimumab therapy in patients with psoriasis and psoriatic arthritis.

Original language	English
Pages (from-to)	492 - 496
Number of pages	5
Journal	British Journal of Dermatology
Volume	151
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2133.2004.06105.x
Publication status	Published - Aug 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2133.2004.06105.x

Cite this

@article{3ce6656edf0e4e3a816976b59e0b909f,

title = "Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab",

abstract = "Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-alpha, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis. We report two patients with long-standing recalcitrant psoriasis and psoriatic arthritis who, after multiple treatment failures with conventional and experimental antipsoriatic medications, both responded to treatment with adalimumab. Significant clinical improvement was noted in both skin and joint disease in the two patients after several weeks of treatment with adalimumab. We are unaware of previous published reports of adalimumab therapy in patients with psoriasis and psoriatic arthritis.",

author = "Chew, {A L} and A Bennett and Smith, {C H} and J Barker and B Kirkham",

year = "2004",

month = aug,

doi = "10.1111/j.1365-2133.2004.06105.x",

language = "English",

volume = "151",

pages = "492 -- 496",

journal = "British Journal of Dermatology",

issn = "1365-2133",

publisher = "John Wiley & Sons, Ltd (10.1111)",

number = "2",

}

TY - JOUR

T1 - Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab

AU - Chew, A L

AU - Bennett, A

AU - Smith, C H

AU - Barker, J

AU - Kirkham, B

PY - 2004/8

Y1 - 2004/8

N2 - Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-alpha, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis. We report two patients with long-standing recalcitrant psoriasis and psoriatic arthritis who, after multiple treatment failures with conventional and experimental antipsoriatic medications, both responded to treatment with adalimumab. Significant clinical improvement was noted in both skin and joint disease in the two patients after several weeks of treatment with adalimumab. We are unaware of previous published reports of adalimumab therapy in patients with psoriasis and psoriatic arthritis.

AB - Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-alpha, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis. We report two patients with long-standing recalcitrant psoriasis and psoriatic arthritis who, after multiple treatment failures with conventional and experimental antipsoriatic medications, both responded to treatment with adalimumab. Significant clinical improvement was noted in both skin and joint disease in the two patients after several weeks of treatment with adalimumab. We are unaware of previous published reports of adalimumab therapy in patients with psoriasis and psoriatic arthritis.

UR - http://www.scopus.com/inward/record.url?scp=4544317926&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2004.06105.x

DO - 10.1111/j.1365-2133.2004.06105.x

M3 - Article

SN - 1365-2133

VL - 151

SP - 492

EP - 496

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -

Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this